GEN began operations in Russia in 2014 and opened its Russian representation office in March 2020 to expand its portfolio. With its innovative and specialised drugs, which it both manufactures and distributes, GEN established its presence in the market. In 2017, it received the GMP Compliance Certificate from the Ministry of Industry and Trade of the Russian Federation.